Upstream Bio, Inc. last reported quarterly results on Aug 11, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $773,000 (-17.5% year over year) and diluted EPS of -$0.73. It usually reports 36–43 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 4, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 5, 2025. The company has not filed these results with the SEC yet. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–43 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 11, 2026
42 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-17.5%
|
-40
+0.7%
|
-0.73
+1.4%
|
|
May 13, 2026
43 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
+82.7%
|
-41
-48.8%
|
-0.75
-47.1%
|
|
Feb 11, 2026
42 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1
+9.0%
|
-42
-99.9%
|
-0.79
-63.4%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
+12.5%
|
-34
-111.0%
|
-0.63
+90.9%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
|
-40
|
-0.74
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
1
|
-27
|
-0.51
|
|
Mar 12, 2025
71 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
1
|
-21
|
-0.48
|
|
Nov 7, 2024
38 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1
|
-16
|
-6.96
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UPB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2022626
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.